title: Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors.
abstract: The interaction of ANG II with intrarenal AT1 receptors has been implicated in the progression of diabetic nephropathy, but the role of intrarenal AT2 receptors is unknown. The present studies determined the effect of early diabetes on components of the glomerular renin-angiotensin system and on expression of kidney AT2 receptors. Three groups of rats were studied after 2 wk: 1) control (C), 2) streptozotocin (STZ)-induced diabetic (D), and 3) STZ-induced diabetic with insulin implant (D+I), to maintain normoglycemia. By competitive RT-PCR, early diabetes had no significant effect on glomerular mRNA expression for renin, angiotensinogen, or angiotensin-converting enzyme (ACE). In isolated glomeruli, nonglycosylated (41-kDa) AT1 receptor protein expression (AT1A and AT1B) was increased in D rats, with no change in glycosylated (53-kDa) AT1 receptor protein or in AT1 receptor mRNA. By contrast, STZ diabetes caused a significant decrease in glomerular AT2 receptor protein expression (47.0 +/- 6.5% of C; P < 0.001; n = 6), with partial reversal in D+I rats. In normal rat kidney, AT2 receptor immunostaining was localized to glomerular endothelial cells and tubular epithelial cells in the cortex, interstitial, and tubular cells in the outer medulla, and inner medullary collecting duct cells. STZ diabetes caused a significant decrease in AT2 receptor immunostaining in all kidney regions, an effect partially reversed in D+I rats. In summary, early diabetes has no effect on glomerular mRNA expression for renin, angiotensinogen, or ACE. AT2 receptors are present in glomeruli and are downregulated in early diabetes, as are all kidney AT2 receptors. Our data suggest that alterations in the balance of kidney AT1 and AT2 receptor expression may contribute to ANG II-mediated glomerular injury in progressive diabetic nephropathy.
authors.affiliation: Department of Cellular and Molecular Medicine, Division of Nephrology, The Kidney Research Centre, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: G J
authors.initials: GJ
authors.lastname: Wehbi
authors.forename: J
authors.initials: J
authors.lastname: Zimpelmann
authors.forename: R M
authors.initials: RM
authors.lastname: Carey
authors.forename: D Z
authors.initials: DZ
authors.lastname: Levine
authors.forename: K D
authors.initials: KD
authors.lastname: Burns
mesh_terms: D000809:Angiotensins / Q000378:metabolism*; D000818:Animals; D000900:Anti-Bacterial Agents; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism*; D015536:Down-Regulation / Q000502:physiology*; D007672:Kidney Cortex / Q000378:metabolism; D007678:Kidney Glomerulus / Q000378:metabolism*; D007679:Kidney Medulla / Q000378:metabolism; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000378:metabolism*; D012083:Renin / Q000378:metabolism*; D013311:Streptozocin
chemical_list: D000809:Angiotensins; D000900:Anti-Bacterial Agents; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D013311:Streptozocin; D007703:Peptidyl-Dipeptidase A; D012083:Renin